内科理论与实践

内科理论与实践 >

2025 , Vol. 20 >Issue 04: 316 - 318

DOI: https://doi.org/10.16138/j.1673-6087.2025.04.10

病例报告

利妥昔单抗序贯贝利木单抗治疗神经精神狼疮1例

  • 陈雪 ,
  • 孙明芳 ,
  • 戴欢子
展开
  • 陆军军医大学大坪医院风湿免疫科，重庆 400042
戴欢子 E-mail: daihuanzi@tmmu.edu.cn

收稿日期: 2024-09-13

  网络出版日期: 2025-10-27

基金资助

重庆市自然科学基金面上项目（重点项目）(CSTB2024NSCQ-KJFZZDX0049)

收起

A case of neuropsychiatric lupus successfully treated with sequential therapy of rituximab and belimumab therapy

  • CHEN Xue ,
  • SUN Mingfang ,
  • DAI Huanzi
Expand
  • Department of Rheumatology and Immunology, Daping Hospital, Army Military Medical University, Chongqing 400042, China

Received date: 2024-09-13

  Online published: 2025-10-27

Fold

摘要

神经精神狼疮是系统性红斑狼疮严重并发症，尤其是累及中枢神经系统时，死亡率明显增加，且目前尚无标准治疗方案。本文报道1例以精神行为异常、谵语为主要表现的神经精神狼疮患者，予以利妥昔单抗序贯贝利木单抗治疗后患者症状缓解，实验室及影像学指标明显改善，为神经精神狼疮的治疗提供了新策略。

关键词： 系统性红斑狼疮; 神经精神狼疮; 利妥昔单抗; 贝利木单抗

本文引用格式

陈雪 , 孙明芳 , 戴欢子 . 利妥昔单抗序贯贝利木单抗治疗神经精神狼疮1例[J]. 内科理论与实践, 2025 , 20(04) : 316 -318 . DOI: 10.16138/j.1673-6087.2025.04.10

Abstract

Neuropsychiatric lupus erythematosus (NPSLE) is a severe complication of systemic lupus erythematosus, it leads to a significantly increased mortality rate when it affects the central nervous system. Currently, there is no established standard treatment regimen for this condition. This article reports a case study of a patient with NPSLE, who primarily presented abnormal mental and behavioral and incoherent speech. Following sequential treatment with rituximab and belimumab, the patient’s symptoms were relieved and laboratory imaging indicators were significantly improved, which provided a new potential therapeutic strategy for NPSLE.

Key words： Systemic lupus erythematosus; Neuropsychiatric lupus erythematosus; Rituximab; Belimumab

参考文献

[1] Govoni M, Bortoluzzi A, Padovan M, et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus[J]. J Autoimmun, 2016,74:41-72.
[2] Govoni M, Hanly JG. The management of neuropsychiatric lupus in the 21st century: still so many unmet needs?[J]. Rheumatology (Oxford), 2020,59 Suppl 5 :v52-v62.
[3] The American College of Rheumatology. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes[J]. Arthritis Rheum, 1999, 42(4):599-608.
[4] Wang M, Wang Z, Zhang S, et al. Progress in the pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus[J]. J Clin Med, 2022, 11(17):4955.
[5] Zameer A, Hoffman SA. B and T cells in the brains of autoimmune mice[J]. J Neuroimmunol, 2004, 146(1-2):133-139.
[6] Wen J, Doerner J, Weidenheim K, et al. TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice[J]. J Autoimmun, 2015,60:40-50.
[7] Mok MY, Chan EY, Wong WS, et al. Intrathecal immunoglobulin production in patients with systemic lupus erythematosus with neuropsychiatric manifestations[J]. Ann Rheum Dis, 2007, 66(6):846-847.
[8] Wise LM, Stohl W. Belimumab and rituximab in systemic lupus erythematosus: a tale of two B cell-targeting agents[J]. Front Med (Lausanne), 2020,7:303.
[9] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(6):736-745.
[10] Boyce EG, Fusco BE. Belimumab: review of use in systemic lupus erythematosus[J]. Clin Ther, 2012, 34(5):1006-1022.
[11] Kodera T, Tsutsumi T, Oka Y, et al. Clinical efficacy of belimumab in patients with systemic lupus erythematosus and headache. A report of two cases[J]. Mod Rheumatol Case Rep, 2022, 6(1):25-28.
[12] Plü? M, Tampe B, Niebusch N, et al. Clinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus[J]. Front Med (Lausanne), 2020,7:222.
[13] Cheng H, Zhao CS, Yan CL, et al. Efficacy of Belimumab for refractory systemic lupus erythematosus (SLE) involving the central nervous system[J]. Eur J Intern Med, 2021,92:117-120.
[14] Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse[J]. Arthritis Rheum, 2006, 54(3):723-732.
[15] Cambridge G, Isenberg DA, Edwards JC, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response[J]. Ann Rheum Dis, 2008, 67(7):1011-1016.
[16] Ramsk?ld D, Parodis I, Lakshmikanth T, et al. B cell alterations during BAFF inhibition with belimumab in SLE[J]. EBioMedicine, 2019,40:517-527.
[17] Kraaij T, Kamerling SWA, de Rooij ENM, et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus[J]. J Autoimmun, 2018,91:45-54.
[18] Petricca L, Gigante MR, Paglionico A, et al. Rituximab followed by belimumab controls severe lupus nephritis and bullous pemphigoid in systemic lupus erythematosus refractory to several combination therapies[J]. Front Med (Lausanne), 2020,7:553075.
Options
文章导航

/

〈 〉